Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Marginal Zone Lymphoma
Drug:
Kymriah (tisagenlecleucel-T)
(
CD19-targeted CAR-T immunotherapy
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Marginal Zone Lymphoma: Suggested treatment regimens…Anti-CD19 CAR T-cell therapy (only after ≥2 prior chemoimmunotherapy regimens…Tisagenlecleucel
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login